Li Kang Biomedical Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was TWD 386.97 million compared to TWD 456.72 million a year ago. Revenue was TWD 386.97 million compared to TWD 456.72 million a year ago.

Net income was TWD 51.44 million compared to TWD 69.27 million a year ago. Basic earnings per share from continuing operations was TWD 2.2095 compared to TWD 2.9714 a year ago. Diluted earnings per share from continuing operations was TWD 2.2 compared to TWD 2.9524 a year ago.